Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a ‘Buy’ rating and a $72 price target. The research ...

Zai Lab Limited (NASDAQ:ZLAB) is one of the 10 biotech stocks screaming a buy. On June 17, the company delivered positive ...

Investing.com -- Lipella Pharmaceuticals Inc (OTC: LIPO) stock plunged 23% after the clinical-stage biotechnology company was delisted from the Nasdaq Capital Market due to rule violations related to ...

The Company was notified by the Hearings Panel of its determination to delist the Company's common stock effective today.

UroGen Pharma posted 0% EPS growth in the latest quarterly report, while sales growth came in at 8%. The company earns the No ...

Parataxis is launching a Bitcoin treasury platform for South Korean institutional investors, which saw Bridge Bio’s stock ...

Beam Therapeutics shows promising BEACON trial results in SCD, backed by strong cash reserves and pipeline momentum. See why ...

However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current ...

As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis ...

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin” or the "Company”), a late-stage pharmaceutical company with a broad ...

FST Corp's sales spike when golfers use FST equipment to win major tournaments. Rising expenses outpace revenue growth, ...

Zealand Pharma A/S’s shares have slid to a near 18-month low, as the Danish biotech’s experimental weight-loss drug faces mounting competition and a long wait ahead for crucial trial results.